Ocular Therapeutix Net Income

Ocular Therapeutix (OCUL) currently reports a net income of $-300M as of June 2026. That compares with $-220M in the prior-year period — down 39.1% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Ocular Therapeutix's net income history and peer comparisons.

Ocular Therapeutix's net income decreased from $-220M to $-300M — a 39.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ocular Therapeutix's net income of $-300M is lower than the Healthcare sector average of $16B. That is roughly 101.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Ocular Therapeutix reported $-300M in net income as of June 2026. That compares with $-220M in the prior-year period — down 39.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-300M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Ocular Therapeutix, and consider following OCUL for alerts when major investors trade the stock.